{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:43:50Z","timestamp":1772621030764,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Cutaneous metastatic carcinoma is a malignant tumor that originates outside the skin. Studies have found that the most common primary tumor in female patients with cutaneous metastatic carcinoma is breast cancer. Cutaneous metastatic carcinoma spreads to the adjacent skin through blood vessels, lymphatics, or interstitial spaces. It forms ulcerative or nodular lesions. Carcinoma en cuirasse is characterized by extensive induration and sclerosis of the skin, resembling armor, and is a rare form of cutaneous metastatic carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns<\/jats:title>\n                    <jats:p>We report a rare case of a 59-year-old patient who developed dark red nodules on the skin of the breast in 2013. These nodules gradually enlarged, ultimately causing the breast to lose its normal shape. Subsequently, the skin on the chest and back thickened, accompanied by local erosion and ulceration that gave the skin a hardened, armor-like appearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses<\/jats:title>\n                    <jats:p>Ultrasound and chest CT suggest diffuse infiltration in the subcutaneous fat of the neck and thorax. Core-needle biopsy pathology reveals infiltrating micropapillary carcinoma, with tumor invasion of the dermis, the tumor clearly originates from the breast.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>The first-line treatment for advanced-stage breast cancer is the combination of cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6 inhibitors) and aromatase inhibitors (AIs), specifically Abemaciclib and Anastrozole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>The patient has been treated for 44 months, and the disease has significantly improved. This is evidenced by the absence of tumor tissue in the biopsy of the affected skin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons<\/jats:title>\n                    <jats:p>Breast cancer cutaneous metastasis, although rare, requires high vigilance, especially in the HER2-negative Luminal B subtype. The efficacy data on CDK4\/6 inhibitors combined with endocrine therapy as a standard regimen for cutaneous metastasis is still lacking. It is necessary to enhance mechanistic studies and clinical observations, taking molecular characteristics into account.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1742907","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:19Z","timestamp":1772602879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Carcinoma en cuirasse\u2014widespread cutaneous metastases from breast adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Chongyi","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoke","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.08.008","article-title":"Cutaneous metastasis","volume":"33","author":"Strickley","year":"2019","journal-title":"Hematology\/oncology Clinics North America"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.07.012","article-title":"Epidemiologic and histopathologic characterization of cutaneous metastases in patients who visited 2 hospitals in santiago de Chile between 2005 and 2017","volume":"110","author":"Kaplan","year":"2019","journal-title":"Actas dermo-sifiliograficas"},{"key":"B3","article-title":"Diffuse cutaneous breast cancer metastases resembling subcutaneous nodules with no surface changes","volume":"101","author":"Mayer","year":"2018","journal-title":"Cutis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2009.0662","article-title":"Carcinoma en cuirasse of the breast","volume":"19","author":"Carlesimo","year":"2009","journal-title":"Eur J dermatology: EJD"},{"key":"B5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4103\/1947-2714.118918","article-title":"The presentation, pathology, and current management strategies of cutaneous metastasis","volume":"5","author":"Wong","year":"2013","journal-title":"North Am J Med Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e20301","DOI":"10.7759\/cureus.20301","article-title":"Pleomorphic appearance of breast cancer cutaneous metastases","volume":"13","author":"Cohen","year":"2021","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.030","article-title":"Cutaneous manifestations of breast cancer","volume":"43","author":"Tan","year":"2016","journal-title":"Semin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000331417","article-title":"Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between egfr overexpression and skin manifestations","volume":"81","author":"Kong","year":"2011","journal-title":"Oncology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02590.x","article-title":"Cutaneous metastases from different internal Malignancies: A clinical and prognostic appraisal","volume":"22","author":"Hu","year":"2008","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.10.009","article-title":"Cutaneous metastases from solid neoplasms - literature review","volume":"98","author":"Souza","year":"2023","journal-title":"Anais brasileiros dermatologia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.23.5090","article-title":"Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts","volume":"6","author":"Perez-Pinera","year":"2007","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13000-024-01509-x","article-title":"Molecular alterations and prognosis of breast cancer with cutaneous metastasis","volume":"19","author":"Xu","year":"2024","journal-title":"Diagn Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how braf inhibition generates drug-tolerant microenvironments with high integrin B1\/fak signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for hr-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.6155","article-title":"Monarch 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-4046-y","article-title":"Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: ten-year audit of single centre experience","volume":"161","author":"Bourke","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-1073","article-title":"Elacestrant in er+, her2- metastatic breast cancer with esr1-mutated tumors: subgroup analyses from the phase iii emerald trial by prior duration of endocrine therapy plus cdk4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/s1470-2045(23)00673-3","article-title":"Expression of concern-alpelisib plus fulvestrant in pik3ca-mutated, hormone receptor-positive advanced breast cancer after a cdk4\/6 inhibitor (Bylieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"25","year":"2024","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1742907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:41:34Z","timestamp":1772602894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1742907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1742907"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1742907","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1742907"}}